Needham Reiterates Buy Rating on Recursion Pharmaceuticals, Keeps $8 Target
Needham reiterated its Buy rating and $8.00 price target on Recursion Pharmaceuticals. The target implies 130.9% upside from the Oct. 16 close of $3.46.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.